Hologic, Inc. (NASDAQ:HOLX) Given Average Rating of “Moderate Buy” by Analysts

Hologic, Inc. (NASDAQ:HOLX) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $87.60.

Several equities research analysts have weighed in on HOLX shares. Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Evercore ISI increased their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. lifted their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th.

Insider Buying and Selling

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock valued at $1,469,973 over the last ninety days. Company insiders own 1.75% of the company’s stock.

Institutional Investors Weigh In On Hologic

Hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in shares of Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares during the last quarter. Norges Bank purchased a new position in Hologic in the fourth quarter worth about $217,529,000. The Manufacturers Life Insurance Company lifted its stake in shares of Hologic by 21.6% in the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after buying an additional 450,190 shares in the last quarter. Black Creek Investment Management Inc. grew its holdings in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Hologic by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after acquiring an additional 124,739 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.8 %

NASDAQ HOLX opened at $82.40 on Friday. The firm has a market cap of $19.23 billion, a PE ratio of 42.04, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. Hologic has a 1-year low of $64.02 and a 1-year high of $84.67. The stock has a 50-day moving average of $80.63 and a 200-day moving average of $77.01. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.93 earnings per share. As a group, sell-side analysts forecast that Hologic will post 4.09 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.